Search results for: Market Access
Filter search results
Innovative Chemical Extensions: The Economic Basis of Pharmaceutical Progress
1 December 1988
This is an important paper based on original economic analyses of the new entrants to various pharmaceutical sub-markets. To use a sporting analogy, it indicates that the first one away…
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
…were in “active” development, and 17 of which were marketed. The majority of the products in active development were classified as disease modifying (66%) rather than symptom modifying (31%), but…
Dementia: The R&D Landscape
1 November 2015
…of which were in “active” development, and 17 of which were marketed. The majority of the products in active development were classified as disease modifying (66%) rather than symptom modifying…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to market with multiple indications…
Spotlight on OHE: Measuring Preferences, HTA Benchmarking, Value-Based Pricing, and Rationing
13 October 2011
…R&D in global health. Value-based pricing (VBP), due to be implemented in the UK for newly marketed medicines as from 2014, remains a key focus of OHE activities. At a…
Professor Nancy Devlin Appointed to PHIN’s Board of Directors
9 October 2015
…to implement the information remedies set out in the Private Healthcare Market Investigation Order 2014. PHIN collect and analyse data from their member organisations to create accessible information, designed to…
Changes in Determining Medicines Pricing in France, Germany and the UK
24 January 2013
New requirements for health technology assessment in Europe have important implications for markets and for access to new medicines. At a recent conference, OHE’s Jorge Mestre-Ferrandiz summarised changes implemented or…
Mikel Berdud
26 February 2015
…interests are the role of intellectual property rights and other pull/push incentives in fostering pharmaceutical innovation; the regulation of pharmaceutical markets and its impact of access to innovation and R&D…
Around The World in HTAs: Italy – What’s Next?
20 April 2023
…exception of a few advanced therapies. Pharmaceutical companies may also apply for innovativeness status that provides immediate access to regional markets and a dedicated fund. Drugs innovativeness is appraised on…